Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
47.00
+0.80 (1.73%)
Sep 12, 2025, 4:00 PM EDT - Market closed
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $11.48M in the quarter ending June 30, 2025, a decrease of -55.26%. This brings the company's revenue in the last twelve months to $44.71M, down -49.51% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$44.71M
Revenue Growth
-49.51%
P/S Ratio
83.28
Revenue / Employee
$237,824
Employees
188
Market Cap
3.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
KYMR News
- 4 days ago - Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript - Seeking Alpha
- 10 days ago - Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 17 days ago - Kymera Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 4 weeks ago - The Best Small-Cap Stocks to Buy Now - Kiplinger
- 4 weeks ago - Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Pricing of $250 Million Public Offering - GlobeNewsWire